Literature DB >> 2908822

Alpha 1- and alpha 2-adrenoceptor mediated vasoconstriction in the forearm: differences between normotensive and hypertensive subjects.

K Jie1, P van Brummelen, P Vermey, P B Timmermans, P A van Zwieten.   

Abstract

Alpha 1- and alpha 2-adrenoceptor mediated vasoconstriction were compared between 13 patients with essential hypertension and 13 normotensive controls, matched for age and sex. For this purpose changes in forearm blood flow induced by infusion of the selective alpha 1-adrenoceptor agonist methoxamine, the selective alpha 2-adrenoceptor agonist B-HT 933, the catecholamines adrenaline and noradrenaline and the alpha 2-adrenoceptor antagonist yohimbine were measured in both study groups. The catecholamines were infused together with propranolol to avoid beta-adrenergic effects. Forearm blood flow was measured by plethysmography. All agonists produced a dose-dependent vasoconstriction which was more pronounced in the hypertensive subjects but no preference was found for either the alpha 1- or alpha 2-adrenoceptor mediated vasoconstriction. Yohimbine induced a greater vasodilatation in the normotensive subjects. The greater vasoconstriction in the hypertensive patients could be explained by structural vascular changes. No evidence was found for an important role of alpha 2-adrenoceptor mediated vasoconstriction in essential hypertension.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2908822

Source DB:  PubMed          Journal:  J Hypertens Suppl        ISSN: 0952-1178


  2 in total

1.  Defective venous beta-adrenergic response in borderline hypertensive subjects is corrected by a low sodium diet.

Authors:  R D Feldman
Journal:  J Clin Invest       Date:  1990-03       Impact factor: 14.808

2.  Sympathetic-transduction in untreated hypertension.

Authors:  Matthew D Kobetic; Amy E Burchell; Laura E K Ratcliffe; Sandra Neumann; Zoe H Adams; Regina Nolan; Angus K Nightingale; Julian F R Paton; Emma C Hart
Journal:  J Hum Hypertens       Date:  2021-08-27       Impact factor: 3.012

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.